Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-marketing Surveillance of Administration of Botulinum Toxin Type B(NerBloc)-Investigation of the Clinical Condition and Safety in Patients With Cervical Dystonia

NCT02175693 is registered in ClinicalTrials.gov with Eisai Co., Ltd. as lead sponsor.

NCT NCT02175693
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02175693 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-marketing Surveillance of Administration of Botulinum Toxin Type B(NerBloc)-Investigation of the Clinical Condition and Safety in Patients With Cervical Dystonia
Lead sponsor
Eisai Co., Ltd.
Phase
Observational
Overall status
Completed
Start date
April 2, 2013
Completion date
June 30, 2019
Enrollment
1,647 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cervical dystonia